22 studies found for:    EGFRvIII
Show Display Options
Rank Status Study
1 Recruiting Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
Condition: Patients With Residual or Reccurent EGFRvIII+ Glioma
Intervention: Biological: CART-EGFRvIII T cells
2 Recruiting A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Conditions: Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component;   Recurrent Glioblastoma;   Relapsed Glioblastoma
Interventions: Drug: Bevacizumab;   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: KLH
3 Recruiting White Blood Cells With Anti-EGFR-III for Malignant Gliomas
Conditions: Malignant Glioma;   Glioblastoma;   Brain Cancer
Interventions: Biological: Anti-EGFRvIII CAR transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
4 Recruiting Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II Clinical Trial.
Condition: Recurrent Glioblastoma
Intervention: Drug: PF-299804 (Dacomitinib)
5 Active, not recruiting Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Conditions: Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: Temozolomide;   Drug: KLH
6 Recruiting AMG 595 First-in-Human in Recurrent Gliomas
Conditions: Advanced Malignant Glioma;   Anaplastic Astrocytomas;   Glioblastoma Multiforme
Intervention: Drug: AMG 595
7 Terminated Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
Conditions: Brain Cancer;   Brain Stem Tumors;   Pontine Tumors
Intervention: Biological: Rindopepimut
8 Terminated S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer
Conditions: Brain Tumors;   Gastric Cancer;   Ovarian Cancer;   Prostate Cancer
Interventions: Biological: KLH;   Biological: GMCSF
9 Completed
Has Results
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Erlotinib
10 Active, not recruiting
Has Results
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Condition: Malignant Neoplasms of Brain
Interventions: Biological: PEP-3 vaccine;   Biological: sargramostim;   Drug: Temozolomide
11 Recruiting Phase I Study of Safety and Immunogenicity of ADU-623
Conditions: Astrocytic Tumors;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Brain Tumor
Interventions: Biological: Cohort 1;   Biological: Cohort 2;   Biological: Cohort 3;   Drug: Antibiotics
12 Completed Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
Condition: Malignant Neoplasms of Brain
Interventions: Biological: PEP-3-KLH conjugate vaccine;   Biological: daclizumab;   Drug: temozolomide;   Other: placebo;   Biological: PEP-3-KLH
13 Active, not recruiting Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme
Condition: Malignant Glioma
Interventions: Drug: CDX-110 with GM-CSF;   Drug: temozolomide
14 Terminated Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: erlotinib hydrochloride
15 Active, not recruiting EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Condition: Brain Cancer
Intervention: Drug: erlotinib
16 Terminated Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Diffuse Astrocytoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Oligodendroglioma;   Recurrent Adult Brain Tumor
Interventions: Drug: erlotinib hydrochloride;   Drug: isotretinoin;   Other: laboratory biomarker analysis;   Genetic: protein expression analysis
17 Recruiting Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention: Drug: Erlotinib
18 Completed Genistein in Patients Who Are Undergoing Surgery for Bladder Cancer
Condition: Bladder Cancer
Interventions: Dietary Supplement: genistein;   Other: placebo
19 Completed PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma
Conditions: Head Neck Cancer Squamous Cell Metastatic;   Head Neck Cancer Squamous Cell Recurrent
Intervention: Drug: PF-00299804
20 Recruiting A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus
Condition: Esophageal Squamous Cell Carcinoma
Intervention: Drug: PF804

Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results
Indicates status has not been verified in more than two years